DK2101569T3 - Krystallinsk fast rasagilinbase - Google Patents

Krystallinsk fast rasagilinbase

Info

Publication number
DK2101569T3
DK2101569T3 DK07862906.0T DK07862906T DK2101569T3 DK 2101569 T3 DK2101569 T3 DK 2101569T3 DK 07862906 T DK07862906 T DK 07862906T DK 2101569 T3 DK2101569 T3 DK 2101569T3
Authority
DK
Denmark
Prior art keywords
crystalline solid
rasagiline base
solid rasagiline
base
aminoindan
Prior art date
Application number
DK07862906.0T
Other languages
English (en)
Inventor
Anton Frenkel
Tamas Koltai
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39536623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2101569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK2101569T3 publication Critical patent/DK2101569T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82Purification; Separation; Stabilisation; Use of additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
DK07862906.0T 2006-12-14 2007-12-13 Krystallinsk fast rasagilinbase DK2101569T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87501106P 2006-12-14 2006-12-14
PCT/US2007/025583 WO2008076348A1 (en) 2006-12-14 2007-12-13 Crystalline solid rasagiline base

Publications (1)

Publication Number Publication Date
DK2101569T3 true DK2101569T3 (da) 2012-01-30

Family

ID=39536623

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07862906.0T DK2101569T3 (da) 2006-12-14 2007-12-13 Krystallinsk fast rasagilinbase

Country Status (25)

Country Link
US (4) US7750051B2 (da)
EP (1) EP2101569B1 (da)
JP (1) JP5623081B2 (da)
KR (1) KR101459744B1 (da)
CN (1) CN101557706B (da)
AT (1) ATE528989T1 (da)
AU (1) AU2007334428B2 (da)
CA (1) CA2672414A1 (da)
CY (1) CY1112511T1 (da)
DK (1) DK2101569T3 (da)
EA (1) EA016820B1 (da)
ES (1) ES2375761T3 (da)
HK (1) HK1129276A1 (da)
HR (1) HRP20110980T1 (da)
IL (1) IL198985A0 (da)
MX (1) MX2009006251A (da)
NO (1) NO20092611L (da)
NZ (1) NZ577460A (da)
PL (1) PL2101569T3 (da)
PT (1) PT2101569E (da)
RS (1) RS52183B (da)
SI (1) SI2101569T1 (da)
UA (1) UA97502C2 (da)
WO (1) WO2008076348A1 (da)
ZA (1) ZA200903903B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
MX2007010233A (es) 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
AU2006316585B2 (en) * 2005-11-17 2012-09-20 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
DK2101569T3 (da) 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
CA2723869C (en) 2008-06-02 2013-07-16 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
CN103893160A (zh) 2008-06-13 2014-07-02 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
AU2009260728B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CN101606923B (zh) * 2008-06-20 2013-01-09 重庆医药工业研究院有限责任公司 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
ITMI20081406A1 (it) * 2008-07-29 2010-01-30 Dipharma Francis Srl Forma cristallina di rasagilina e procedimento per la sua preparazione
WO2010059913A2 (en) * 2008-11-20 2010-05-27 Dr. Reddy's Laboratories Ltd. Preparation of rasagiline and salts thereof
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
EP2298277A1 (en) * 2009-09-09 2011-03-23 Labtec GmbH Transdermal patch formulation
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
EP2939669A1 (en) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
KR20120137373A (ko) 2010-04-30 2012-12-20 테이코쿠 팔마 유에스에이, 인코포레이티드 프로필아미노인단 경피 조성물
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
WO2012153349A2 (en) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
CA2851276A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
EP2610239A1 (en) 2012-01-02 2013-07-03 Dr. Reddy's Laboratories Ltd. Preparation Of Rasagiline Hemitartrate
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
CA2882072A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulations of rasagiline
CN104797245B (zh) * 2012-11-02 2018-05-04 帝国制药美国公司 丙炔基氨基茚满透皮组合物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US4529811A (en) * 1981-03-02 1985-07-16 G. D. Searle & Co. Process for isolating organic compounds and lithium salt complexes useful in said process
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CN1031995C (zh) * 1991-01-02 1996-06-12 奥韦特有限公司 N-炔丙基-1-氨基茚满的r-对映体的制法
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
CA2208600A1 (en) 1995-02-01 1996-08-08 Pharmacia & Upjohn Company 2-aminoindans as selective dopamine d3 ligands
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) * 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en) * 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
WO1999037293A2 (en) * 1998-01-27 1999-07-29 Thomas Thomas N Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
IL141690A (en) * 2001-02-27 2004-06-20 Isp Finetech Ltd Process for preparation of rasagiline and its salts
US6543155B2 (en) 2001-03-01 2003-04-08 National Agricultural Research Organization Freeze-dried product and process and apparatus for producing it
US20030087814A1 (en) * 2001-11-05 2003-05-08 Seth Lederman Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
AU2003290838A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
US7875630B2 (en) * 2003-09-03 2011-01-25 Glaxo Group Limited Process salts compositions and use
US7799273B2 (en) * 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2588293C (en) 2004-11-24 2013-07-02 Teva Pharmaceutical Industries Ltd. Rasagiline orally disintegrating compositions
MX2007010233A (es) * 2005-02-23 2007-11-07 Teva Pharma Formulaciones de rasagilina de uniformidad de contenido mejorada.
AU2006316585B2 (en) * 2005-11-17 2012-09-20 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
CN101032474B (zh) 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
US7573834B2 (en) * 2006-05-31 2009-08-11 Alcatel Lucent Method and system for allocating a group bit rate among multiple bonded pairs in a communications network
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
DK2101569T3 (da) 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP2101570B1 (en) * 2006-12-14 2013-02-13 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) * 2008-01-11 2010-08-03 Teva Pharma Formulaciones de rasagilina, su preparacion y uso.
EP2271612B1 (en) 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
AU2009260728B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282720B2 (en) * 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
WO2012058219A2 (en) 2010-10-26 2012-05-03 Teva Pharmaceutical Industries Ltd. Deuterium enriched rasagiline
CA2851276A1 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
CN103857389A (zh) * 2011-10-10 2014-06-11 泰华制药工业有限公司 雷沙吉兰柠檬酰胺
BR112014008552A2 (pt) * 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano

Also Published As

Publication number Publication date
US20150038744A1 (en) 2015-02-05
ATE528989T1 (de) 2011-11-15
EP2101569B1 (en) 2011-10-19
MX2009006251A (es) 2009-10-12
JP2010513282A (ja) 2010-04-30
AU2007334428B2 (en) 2014-05-29
EP2101569A1 (en) 2009-09-23
SI2101569T1 (sl) 2012-02-29
US20080161408A1 (en) 2008-07-03
EA016820B1 (ru) 2012-07-30
CN101557706A (zh) 2009-10-14
EA200970581A1 (ru) 2009-12-30
CA2672414A1 (en) 2008-06-26
KR20090089894A (ko) 2009-08-24
NO20092611L (no) 2009-09-11
US20100145101A1 (en) 2010-06-10
WO2008076348A1 (en) 2008-06-26
US7750051B2 (en) 2010-07-06
NZ577460A (en) 2012-01-12
RS52183B (en) 2012-10-31
CY1112511T1 (el) 2015-12-09
US8614252B2 (en) 2013-12-24
JP5623081B2 (ja) 2014-11-12
CN101557706B (zh) 2013-08-07
US20100144887A1 (en) 2010-06-10
ZA200903903B (en) 2010-08-25
PL2101569T3 (pl) 2012-03-30
HRP20110980T1 (hr) 2012-02-29
ES2375761T3 (es) 2012-03-06
EP2101569A4 (en) 2009-12-02
HK1129276A1 (en) 2009-11-27
UA97502C2 (ru) 2012-02-27
WO2008076348A8 (en) 2008-08-21
KR101459744B1 (ko) 2014-11-20
IL198985A0 (en) 2010-02-17
PT2101569E (pt) 2012-01-13
AU2007334428A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
DK2101569T3 (da) Krystallinsk fast rasagilinbase
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
TW200732349A (en) Anti-OX40L antibodies and methods using same
HK1129277A1 (en) Tannate salt of rasagiline
MX2010002974A (es) Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
NO20080991L (no) Bazedoksifen acetat formuleringer
WO2008057291A3 (en) Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
TW200738649A (en) Calcilytic compounds
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EP2644614A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2006091836A8 (en) Formulations of ladostigil tartrate
UY31103A1 (es) Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones
TW200638932A (en) CCI-779 polymorph and use thereof
ATE539082T1 (de) Oxazinylisoflavonoidverbindungen, medikamente und anwendungen
WO2008015584A3 (en) Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
ATE552832T1 (de) Antidepressivum-propharmaka
TW200640836A (en) Processes for preparing sertraline
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων
BRPI0702869A2 (pt) formas cristalinas da o-desmetilvenlafaxina